Antibiotics and biocides are important tools against pathogenic bacteria. The world has heavily invested in them, and much of our current medical procedures are only possible because of these technologies.

 

However, every time we use these, we risk the development of superbugs or resistant microbes.

 

The Lixa team has discovered a group of ingredients that can switch resistance off via a new biological mechanism that is conserved across bacterial species. 

 

Our NeoX™ small molecule ingredients can be used across bacterial species, resistance mechanisms and antimicrobial class. 

​

This is a game changer, delivering clinical flexibility and tools to fight "untreatable" bacterial infections and biofilm contaminations.  

​

We have 2 drug lead candidates in preparation for Phase 2 clinical trials (respiratory and systemic infections), as well as a series of approaches to address biocorrosion, concrete rot, marine fouling, animal health and home environment hygiene.